Bültmann & Gerriets
Kidney Cancer
von Robert A. Figlin
Verlag: Springer US
Reihe: Cancer Treatment and Research Nr. 116
Gebundene Ausgabe
ISBN: 978-1-4020-7457-8
Auflage: 2003
Erschienen am 31.10.2003
Sprache: Englisch
Format: 241 mm [H] x 160 mm [B] x 19 mm [T]
Gewicht: 559 Gramm
Umfang: 260 Seiten

Preis: 160,49 €
keine Versandkosten (Inland)


Dieser Titel wird erst bei Bestellung gedruckt. Eintreffen bei uns daher ca. am 8. November.

Der Versand innerhalb der Stadt erfolgt in Regel am gleichen Tag.
Der Versand nach außerhalb dauert mit Post/DHL meistens 1-2 Tage.

klimaneutral
Der Verlag produziert nach eigener Angabe noch nicht klimaneutral bzw. kompensiert die CO2-Emissionen aus der Produktion nicht. Daher übernehmen wir diese Kompensation durch finanzielle Förderung entsprechender Projekte. Mehr Details finden Sie in unserer Klimabilanz.
Klappentext
Biografische Anmerkung
Inhaltsverzeichnis

Kidney cancer is a heterogenous disease. This book covers:
-new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques;
-new staging and prognostic capabilities;
-evolving therapeutic options include, cell based vaccine, gene and antibody therapy;
-molecular genetics allow for a better understanding of the various types of kidney cancer. Kidney Cancer is a comprehensive review covering present and future surgical approaches, staging and prognostic factors, currently accepted and future plans for prevention, diagnosis and treatment. Contributing authors to this book are internationally recognized specialists in this disease. This book will be useful to the specialist (oncologist and urologist), primary care physicians, patients and family members dealing with kidney cancer.



Robert A. Figlin, Professor of Medicine, Urology, Departments of Medicine and Urology, Division of Hematology/Oncology, University of California, Los Angeles School of Medicine, USA, holds the Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology. He serves as Medical Director of the Thoracic and Genitourinary Oncology Program. He is a Senior Clinical Investigator in areas of genitourinary and thoracic oncology and has served as Principal Investigator on Phase I, II, and III trials. He serves as Chairman of the UCLA Medical Institutional Review Board and as a member of the UCLA Human Research Policy Board.



I. Introduction.- 1. Molecular Genetics of Kidney Cancer.- 2. Mechanisms of Immune Dysfunction in Renal Cell Carcinoma.- 3. New Algorithms for the Staging of Kidney Cancer.- 4. Basic Biology and Clinical Behavior of Kidney Cancer.- II. Kidney Cancher.: Surgical Approaches.- 5. Nephron Sparing Surgery.- 6. Laparoscopic Radical Nephrectomy AND Minimally Invasive Surgery for Kidney Cancer.- 7. Role of Nephrectomy in Metastatic Kidney Cancer.- III. Metastatic Renal Cell Carcinoma: Current and Future Approaches.- 8. Prognostic Factors for Metastatic Kidney Cancer.- 9. Interleukin-2 Based Therapy for Kidney Cancer.- 10. The Role of Systemic Chemotherapy in the Treatment of Kidney Cancer.- 11. Cell, Gene, and Vaccine Based Strategies in Kidney Cancer.- 12. Monoclonal Antibody Therapy of Kidney Cancer.- 13. Allogeneic Hematopoetic Stem Cell Transplantation for Cytokine Refractory Renal Cell Carcinoma.- 14. Novel Therapies for Renal Cell Carcinoma.


andere Formate
weitere Titel der Reihe